Experimental drug combo aims to outsmart resistant lung cancer
NCT ID NCT02503722
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests a combination of two targeted drugs, sapanisertib and osimertinib, in people with advanced EGFR-mutant non-small cell lung cancer that has stopped responding to osimertinib alone. The main goals are to find the safest dose and understand side effects. About 36 participants will take both pills by mouth to see if the combination can block cancer growth in a new way.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- sapanisertib and osimertinib
- What this could lead to
- If this works, it could point toward a new treatment option for people with a specific type of lung cancer that has stopped responding to current targeted therapy.
- What could go wrong
- This is a very early (Phase 1) trial with only 36 participants, so the main goal is safety and dosing, not yet proof of effectiveness. The combination may cause significant side effects and may not work for everyone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC LUNG NON-SMALL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
BCCA-Vancouver Cancer Centre
Vancouver, British Columbia, V5Z 4E6, Canada
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
-
Smilow Cancer Center/Yale-New Haven Hospital
New Haven, Connecticut, 06510, United States
-
University Health Network-Princess Margaret Hospital
Toronto, Ontario, M5G 2M9, Canada
-
Yale University
New Haven, Connecticut, 06520, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Lung cancer drug shows promise in keeping tumors at bay after chemo
- Lung cancer combo after surgery fails to extend life
- New imaging agent may help doctors see which lung tumors are still growing during immunotherapy
- New drug combo aims to reboot immune system against lung cancer
- Brain cancer trial halted early: can Memory-Sparing radiation help when tumors return?
- Can a smaller dose of this cancer drug still work? new trial aims to find out